• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA grants breakthrough nod to Blackrock Neurotech’s brain-computer interface

FDA grants breakthrough nod to Blackrock Neurotech’s brain-computer interface

November 18, 2021 By Sean Whooley

BlackRock Neurotech ClearPoint Neuro Utah Array
The Utah Array platform [Image from Blackrock Neurotech/ClearPoint Neuro]
Blackrock Neurotech announced that it received FDA breakthrough device designation for its MoveAgain brain-computer interface (BCI) system.

Salt Lake City-based Blackrock Neurotech designed its MoveAgain BCI system to provide immobile patients the ability to control a mouse cursor, keyboard, mobile device/tablet, wheelchair or prosthetic device by only thinking, according to a news release.

The company said the results of its portable MoveAgain BCI could include improved mobility and independence that leads to returning to work, participating in leisure activities and communicating more effectively and quickly.

MoveAgain BCI includes an array implanted in the brain, which decodes movement from neuronal activity. Signals are then transmitted wirelessly to an external device, like a cursor or wheelchair, providing people control of their external environment.

“We look forward to working closely with the FDA to prioritize development of the MoveAgain brain-computer interface system, which will bring us closer to our goal of commercialization in 2022,” Blackrock Neurotech Co-Founder & CEO Marcus Gerhardt said in the release. “Patients with tetraplegia are eager to get access, and we are committed to advancing their ability to increase their independence with our BCI technology.”

Blackrock Neurotech Chair & President Florian Solzbacher added that the company believes it has sufficient safety and efficacy data to support the first applications. Meanwhile, large-scale integration technologies have allowed further miniaturization as the company looks to develop a wireless version.

Solzbacher noted that Blackrock Neurotech aims to submit plans to make the products widely available in 2022.

“We are seeing the beginning of a revolution in the diagnosis and treatment of neurological disorders and disabilities,” Solzbacher said. “Ten years from now, neural implants could be as common as cardiac pacemakers are today — offering patients a whole new world of options that restore their independence.”

Filed Under: Featured, Health Technology, Implants, Neurological, News Well, Software / IT Tagged With: Blackrock Neurotech

More recent news

  • Zimmer Biomet to expand robotic suite with Monogram acquisition
  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy